Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,916.50p on 17-07-2026 at 18:35:10
Change -39.50p -2.02%
Buy 1,918.50p
Sell 1,917.50p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 4,030.00 at 1,916.50p
Day's Volume: 13,825,247
Last Close: 1,916.50p
Open: 1,966.00p
ISIN: GB00BN7SWP63
Day's Range 1,868.00p - 1,982.00p
52wk Range: 1,337.00p - 2,282.00p
Market Capitalisation: £76.77b
VWAP: 1,912.517p
Shares in Issue: 4.01b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 4,030 1,916.50p SI Trade
Suspected SELL Trade
 17:30:50 - 17-Jul-26
Sell* 16,200 1,910.39p SI Trade
Suspected SELL Trade
 17:14:07 - 17-Jul-26
Sell* 18,833 1,911.82p SI Trade
Suspected SELL Trade
 16:40:04 - 17-Jul-26
Buy* 74 1,916.50p Automatic Execution
 16:38:16 - 17-Jul-26
Buy* 18 1,916.50p Automatic Execution
 16:38:13 - 17-Jul-26
Buy* 84 1,916.50p Automatic Execution
 16:37:07 - 17-Jul-26
Buy* 2,171 1,916.50p Automatic Execution
 16:36:01 - 17-Jul-26
Buy* 2,171 1,916.50p Automatic Execution
 16:36:01 - 17-Jul-26
Buy* 2,171 1,916.50p Automatic Execution
 16:35:47 - 17-Jul-26
Sell* 2,849 1,916.50p SI Trade
 16:35:14 - 17-Jul-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
17th Jul 2026 (Fri) 1,966.00 1,982.00 1,868.00 1,916.50 13,825,247
16th Jul 2026 (Thu) 1,904.00 1,958.00 1,896.00 1,956.00 5,092,934
15th Jul 2026 (Wed) 1,920.50 1,929.00 1,903.50 1,916.50 8,355,831
14th Jul 2026 (Tue) 1,956.00 1,957.50 1,905.00 1,920.50 4,279,605
13th Jul 2026 (Mon) 1,960.00 1,983.50 1,934.00 1,953.50 4,209,058
10th Jul 2026 (Fri) 1,963.50 1,981.00 1,954.00 1,961.50 6,365,614
9th Jul 2026 (Thu) 1,960.00 1,982.50 1,951.00 1,959.50 5,592,231
8th Jul 2026 (Wed) 1,990.50 1,990.50 1,964.00 1,979.50 4,243,160
7th Jul 2026 (Tue) 1,998.00 2,031.00 1,982.00 2,003.00 4,183,205
6th Jul 2026 (Mon) 2,025.00 2,048.00 1,967.50 1,983.00 15,157,640
3rd Jul 2026 (Fri) 2,005.00 2,015.00 1,988.00 2,015.00 2,548,103
2nd Jul 2026 (Thu) 1,949.00 2,014.00 1,943.00 2,004.00 17,566,583
1st Jul 2026 (Wed) 1,981.00 1,992.00 1,930.00 1,930.00 8,817,916
30th Jun 2026 (Tue) 1,999.50 2,009.00 1,946.50 1,981.00 13,957,667
29th Jun 2026 (Mon) 1,995.00 1,996.50 1,969.00 1,979.50 9,717,943
26th Jun 2026 (Fri) 1,972.50 1,995.50 1,945.50 1,983.00 13,837,274
25th Jun 2026 (Thu) 1,949.00 1,991.00 1,926.50 1,983.50 8,999,065
24th Jun 2026 (Wed) 1,967.00 1,984.00 1,950.00 1,950.00 5,923,852
23rd Jun 2026 (Tue) 1,915.00 1,971.00 1,911.00 1,957.50 8,305,282
22nd Jun 2026 (Mon) 1,925.00 1,931.50 1,912.00 1,924.50 3,565,700
19th Jun 2026 (Fri) 1,926.00 1,943.00 1,917.00 1,925.50 15,135,955
18th Jun 2026 (Thu) 1,976.00 1,978.50 1,906.00 1,923.00 7,565,324
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
17th Jul 2026 12:00 pm RNS Audit tender conclusion
17th Jul 2026 9:30 am RNS Camlipixant phase III results update
16th Jul 2026 3:30 pm RNS Director/PDMR Shareholding
15th Jul 2026 1:38 pm RNS GSK completes acquisition of Nuvalent, Inc
14th Jul 2026 3:30 pm RNS Director/PDMR Shareholding
13th Jul 2026 3:30 pm RNS Director/PDMR Shareholding
13th Jul 2026 7:00 am RNS Positive Jemperli data in dMMR/MSI-H rectal cancer
10th Jul 2026 11:58 am RNS Hansoh positive Phase III results for Riz-Rez
9th Jul 2026 3:30 pm RNS Director/PDMR Shareholding
9th Jul 2026 10:00 am RNS Directorate change
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

LONDON MARKET MIDDAY: FTSE 100 bucks European AI stock selloff

17th Jul 2026 12:10

(Alliance News) - Stock prices in London were lower at midday on Friday as investors assessed fresh eurozone inflation data and escalating tensions in the Middle East. Read More

GSK ends camlipixant research in RCC as trials show "limited efficacy"

17th Jul 2026 10:55

(Alliance News) - GSK PLC on Friday said it will not progress its development of camlipixant for refractory chronic cough, after phase 3 study data suggested that it "is unlikely to transform patient care". Read More

WINNERS & LOSERS: Vega ups Vodafone stake; GSK drug trial disappoints

17th Jul 2026 10:42

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More

IN BRIEF: GSK completes USD10.6 billion acquisition of Nuvalent

15th Jul 2026 14:59

GSK PLC - London-based pharmaceutical company - Completes takeover of Nuvalent Inc, a Boston, Massachusetts-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies. The total value of the acquisition is about USD10.6 billion. Net of cash acquired, GSK's total investment is about USD9.4 billion. The transaction adds three lung cancer assets to GSK's oncology portfolio, with zidesamtinib and neladalkib "considered potential best-in-class assets", and under Food & Drug Administration review for ROS1-positive and ALK-altered non-small cell lung cancer. GSK says: "Both have received FDA breakthrough therapy and orphan drug designations. If approved, they are expected to launch in 2026 with multi-blockbuster potential." Read More

GSK posts encouraging data for bowel cancer treatment Jemperli

13th Jul 2026 09:32

(Alliance News) - GSK PLC on Monday reported encouraging trial data for its cancer treatment Jemperli, also known as dostarlimab. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,600.37
Change28.13

Login to your account

Forgot Password?

Not Registered